OncoImmunity

OncoImmunityOncoImmunity
OncoImmunity

OncoImmunity

OncoImmunity is a company focused on AI for cancer immunotherapy.

Website
DR 262014ActiveOslo, Norway
Rate
Advertise here

About

NEC Bio B.V. develops groundbreaking therapies for patients globally using advanced AI technologies, focusing on personalized cancer vaccines and next-generation vaccines for infectious diseases. Their core approach involves identifying patient-specific neoantigens for oncology and highly immunogenic antigens for infectious diseases, leveraging proprietary AI/ML technologies like NEC Immune Profiler and NEC B-cell Epitope Predictor. They serve patients with indications including ovarian cancer, head and neck cancer, betacoronaviruses, and tropical diseases.
Frequently asked

What does OncoImmunity do?

NEC Bio B.V. develops groundbreaking therapies for patients globally using advanced AI technologies, focusing on personalized cancer vaccines and next-generation vaccines for infectious diseases. Their core approach involves identifying patient-specific neoantigens for oncology and highly immunogenic antigens for infectious diseases, leveraging proprietary AI/ML technologies like NEC Immune Profiler and NEC B-cell Epitope Predictor. They serve patients with indications including ovarian cancer,…

What is OncoImmunity's valuation?

StartupHub estimates OncoImmunity's effective valuation at $19.1M (range $12.0M to $28.8M, 10% confidence), based on comparable companies in the sector.

How much funding has OncoImmunity raised?

OncoImmunity has raised a total of $5M in funding. The most recent round on record is Seed.

Where is OncoImmunity headquartered?

OncoImmunity is headquartered in Oslo, Norway.

When was OncoImmunity founded?

OncoImmunity was founded in 2014.

Comments

No comments yet. Be the first to share your take.